8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements

Boston Scientific filed an 8‑K on Feb 4, 2026 furnishing a press release (Exhibit 99.1) — press release…

Filed with the SEC on February 4, 2026 · Summarized by InvestorsBot

Boston Scientific filed an 8‑K on Feb 4, 2026 furnishing a press release (Exhibit 99.1) — press release dated Feb 4, 2026. Investors: review the PR for any material updates. 📰 $BSX #8K #MedTech

The 8‑K also includes Exhibit 104 (Inline XBRL cover page tags) and is signed by Susan Thompson (VP, Chief Corporate Counsel) on Feb 4, 2026. 📄 $BSX #XBRL #BostonScientific

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from BOSTON SCIENTIFIC CORP

8‑K (Item 9.01): Boston Scientific ($BSX) on Feb 26, 2026 filed three credit agreements — two Credit…

8-K · February 26, 2026

Boston Scientific ($BSX) 8-K filed 2026-02-26: Item 2.03 confirms creation of a direct financial…

8-K · February 26, 2026

Boston Scientific ($BSX) terminated its prior 2021 Revolving Credit Agreement on Feb 26, 2026 after…

8-K · February 26, 2026

BREAKING: $BSX secures an $11B credit package to fund the Penumbra acquisition & bolster liquidity — $3B…

8-K · February 26, 2026

8‑K filed 2/23/2026: Boston Scientific attached Exhibit 99.1 (press release dated Feb 23, 2026) and…

8-K · February 23, 2026

On Feb 18, 2026 Boston Scientific's Board approved a $4.0B increase to its repurchase authorization,…

8-K · February 23, 2026